Montag & Associates’s Exelixis EXEL Stock Holding History

Montag & Associates’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-38	Closed	-$610	–	939
2022 Q4	$610	Buy	+38	New	+$620	﹤0.01%	923

Other funds holding EXEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Montag & Associates's EXEL Position: Q1 2023 in Review

Montag & Associates sold out of Exelixis (EXEL) in Q1 2023, closing a stake of 38 shares — an estimated $610 sold.

Montag & Associates first reported a position in EXEL in Q4 2022 and held it in 1 quarter. The position peaked at $610 in Q4 2022. 363 funds tracked by Wall St. Rank hold EXEL as of Q1 2023.

Montag & Associates reported no remaining Exelixis position as of Q1 2023 after selling out during the quarter.
Montag & Associates sold 38 Exelixis shares in Q1 2023, an estimated $610.
Montag & Associates first reported a position in Exelixis in Q4 2022 and held it in 1 quarter.
Montag & Associates's Exelixis position peaked at $610 in Q4 2022.
363 funds tracked by Wall St. Rank held Exelixis as of Q1 2023.

Based on Montag & Associates's 13F filing for Q1 2023, filed 11 May 2023.